Diabetes mellitus. Diabetes mellitus due to underlying condition
Conditions
Interventions
Intervention 1: Intervention group: Verapamil 40mg , 3 times a day for 3 months. Intervention 2: Control group: Placebo ,3 times a day for 3 months.
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Signature of consent by patients Age between 20 and 65 years Elapsed at least three months from detection of T2DM Baseline A1c <8.5%
Exclusion criteria
Exclusion criteria: Pregnancy and lactation Uncompensated heart failure myocardial infarction or evidence of ischemic heart disease or other serious cardiac disease within the 12 weeks before randomization History of epilepsy, cancer, cystic fibrosis, sickle cell anemia, peripheral vascular disease or cerebrovascular disease known left ventricular dysfunction hypotension (systolic pressure 1.5 mg/dl ,GFR 1.5 x ULN Hypersensitivity to verapamil or any component of the formulation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of expression of GLP-1R mRNA. Timepoint: Before the intervention begins,Days 10,20,30 and 90. Method of measurement: Real-time PCR.;Frequency of expression of miR-204. Timepoint: Before the intervention begins,Days 10,20,30 and 90. Method of measurement: Real-time PCR.;Frequency of expression of TXNIP mRNA. Timepoint: Before the intervention begins,Days 10,20,30 and 90. Method of measurement: Real-time PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarrokh Ramesh
Ahvaz University of Medical Sciences
Outcome results
None listed